메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions; marks new refractive and cataract milestones

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS from Sept. 12 - 15 in Copenhagen, Denmark: EFFICIENT, CONFIDENT DECISION MAKING: introducing AI-powered CIRRUS® PathFinder™ clinical support tool now CE mark approved; presenting a fully integrated diagnostic and SLT therapeutic solution for managing comorbid cataract/glaucoma patients. NEW STANDARDS IN SURGICAL EXCELLENCE: showcasing the DORC EVA NEXUS™ dual strategy surgical platform as part of ZEISS's expanding surgical workflow solutions. IMPROVED PREDICTABILITY OUTCOM
- 김갑성 기자
- 2025-09-02 20:00
SK bioscience Submits IND for Phase 3 Trial of 2-Dose Varicella Vaccine Reflecting Global Standard Shift

Approximately 800 children aged 12 months to 12 years in Korea and abroad, aiming for completion by 2027 Rising demand for 2-dose regimen as international standards amid projected global market growth to USD 6.3 billion by 3034 SKBS continues strategic R&D to enhance global vaccine competitiveness of its vaccine pipelines SEONGNAM, South Korea, Sept. 2, 2025 -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it has submitted an IND (Investigational New Drug application)
- 김갑성 기자
- 2025-09-02 19:00
Ascletis to Present 28-day Multiple Ascending Dose Study Results of Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting

[ 메디채널 김갑성 기자 ] - Ascletis to present data from the U.S. Phase Ib clinical study of ASC30 oral tablet in oral discussion - On track to report topline data from Phase IIa clinical study of ASC30 oral tablet in participants with obesity or overweight in the fourth quarter of 2025 HONG KONG, Sept. 2, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that data from its 28-day multiple ascending dose study of its oral small molecule GLP-1 receptor (GLP-1R) agonist ASC30 (NCT06680440) will be presented in a short oral discussion at the 61st European Associ
- 김갑성 기자
- 2025-09-02 18:00
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights

SHANGHAI, Sept. 2, 2025 -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally "undruggable" protein–protein interactions and complex receptors, while opening new avenues for oral drug discovery. With global investment in peptide pipelines steadily
- 김갑성 기자
- 2025-09-02 17:52
Nuffield Holdings Welcomes Strategic Shareholders to Drive Next Phase of Regional Growth

[ 메디채널 김갑성 기자 ] Capital injection to accelerate M&A, AI-led operations, and expansion across Southeast Asia and the Middle East. SINGAPORE, Sept. 2, 2025 -- Nuffield Holdings is pleased to announce the appointment of Mr Liu Song and Ms Zhang Na as new shareholders, marking a pivotal moment in the Group's regional growth strategy. This investment brings in both capital and strategic insight, enabling Nuffield to accelerate mergers and acquisitions, scale operations, and enhance its leadership in Southeast Asia's healthcare sector. Experienced and Visionary Partners M
- 김갑성 기자
- 2025-09-02 16:45
Akeso Announces Completion of Patient Enrollment in Phase III Clinical Trial for Ivonescimab as First-Line Treatment for Biliary Tract Cancer Compared to PD-L1 Therapy

HONG KONG, Sept. 2, 2025 -- Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study evaluating ivonescimab, in combination with standard therapy, against durvalumab (PD-L1) combination therapy, for the first-line treatment of advanced biliary tract cancer (BTC) (AK112-309/HARMONi-GI1). This Phase III trial is being conducted in China. Ivonescimab has previously shown significant positive results in the randomized, double-blind, controlled Phase III study (HARMONi-2), where it was compared he
- 김갑성 기자
- 2025-09-02 16:00
Jungbunzlauer to acquire from International Flavors & Fragrances, Inc. multipurpose site in Thomson, IL

– establishing U.S. manufacturing footprint – BASEL, Switzerland, Sept. 2, 2025 -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients from natural sources, announced today the signing of a binding and definitive agreement to acquire the multipurpose production site in Thomson, IL from International Flavors & Fragrances, Inc. (IFF). "This acquisition is an important step in delivering on our strategic capacity expansion in North America," said Bruno Tremblay, Chief Executive Officer of Jungbunzlauer. "Establishing a U.S. manufactu
- 황정호 기자
- 2025-09-02 15:00
Heartbeats: 230,000 Views for Dr. Kiat's Everyday Lunch - A Viral Lesson That Science Has No Borders

SYDNEY, Sept. 2, 2025 -- A humble lunch video from world-renowned cardiologist Dr. Hosen Kiat has captured more than 230,000 views on Chinese social media Little Red Book. Shared as part of his new digital wellness initiative with Heartbeats, the "real-style" post featured nothing more than a cup of black coffee, a vegetarian sandwich, steamed vegetables, and mushrooms - yet it sparked a wave of engagement across cultures. Watch the original post here. Despite being filmed in English, the clip resonated deeply with Chinese audiences, proving that authentic science-based healt
- 김갑성 기자
- 2025-09-02 10:08
SteriLance Safety Lancets Adopted Across Thailand's Public-Hospital Channels

BANGKOK, Sept. 2, 2025 -- SteriLance Medical announced that its safety lancet portfolio — PRESS PLUS, IMPRESS and LITE3 — has been adopted within Thailand's public-hospital channels following a tender awarded by a nationally recognized humanitarian organization. Supply and post-market support are being delivered through an authorized local distributor holding Thai FDA registrations. Engineered to reduce accidental needle exposure and improve user comfort in high-throughput settings, SteriLance safety lancets feature single-use auto-retraction and low-pain skin entry, supporting
- 김갑성 기자
- 2025-09-02 08:59
LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

Secures third contract this year, reinforcing global competitiveness and expanding strategic partnerships SEOUL, South Korea and SYRACUSE, N.Y., Sept. 2, 2025 -- LOTTE BIOLOGICS (CEO James Park) today announced that it has entered a late-stage to commercial contract manufacturing partnership with a U.S.-based global biopharmaceutical company. The partnership covers a late-stage Phase 3 program that is advancing into multiple new indications, and extends to commercial supply following potential regulatory approvals. By aligning with its partner's meaningful
- 김갑성 기자
- 2025-09-02 08:00

이전

71 72 73 74 75 76 77 78 79 80

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 09시 20분